webinar
Oct. 27-28, 2025, Boston, MA, USA - Booth 114.
Read More

Calicheamicins

Products Catalog Download PDF

As a class of novel antitumor antibiotics, enediyne antibiotics possess novel structure and unique action mechanism. The discovered enediyne antibiotics include Calicheamicins (CLMs), Kedarcidins, Dynemicins, Esperamicins, Neocarzinostatins (NCSs) and Lidamycins (LDMs) etc. The research indicated that enediyne antibiotics have good inhibitory activities against multiple tumors, especially blood tumors.

Category
By SubCategory
By Functional Group
By Formula Weight
Filtered by
Clear All
Background
Why BOC Sciences

Comprehensive one-stop antibody-drug conjugate service platform

Large Stock

More than 1000+ high-purity products in inventory

Large Stock

Global Delivery

Warehouses in multiple cities to ensure fast delivery

Large Stock

mg to kg

Qualified facilities & equipment of cGMP laboratory

mg to kg

24/7 Technical Support

Strict process parameter control to ensure product quality

Large Stock

Chemical Structural Characteristics of Calicheamicins

Calicheamicins (CLMs) was isolated from the fermentation broth of a rare actinomycete micromonospora echinospora. It is a small molecule fat soluble compound, which has relatively high stability. The average molecular weight of CLMs is 1500 and has a rigid bicyclic with two hydroxyl side chains (R1 and R2), in which CLMs γ1is applied most clinically due to its strongest activities. The molecular structure of CLMs contains an enediyne core of 1,5-diyne-3-ene, a methyl trisulfide, a fully substituted benzene and four glycosides. As the recognizer and transmitter of CLMs, the auxiliary group (oligosaccharide fragment) in the molecule tightly binds the drug molecule to DNA. Enediyne core structure is an active section of antitumor activity, which is an efficient DNA cleaver.

Mechanism of Action of Calicheamicins

Calicheamicins (CLMs) don’t directly cause DNA breakage. It requires an activation process to transform the structure into an active radical intermediate. The interaction pathway between CLMs with DNA can be divided into three steps: drug binding with DNA, drug activation and DNA strand breakage. CLMs first binds to DNA through the oligosaccharide group to embed drug molecules into the small groove of DNA double helix, thereby completing activation process by Bergman cyclization. Then, the hydrogen atoms on the DNA skeleton are rapidly captured by the diradical, causing DNA breakage and resulting in cytotoxicity. When DNA strand break, the enediyne core structure of CLMs plays a decisive role, and methyl trisulfide stimulates the activation of enediyne core.

Application of Calicheamicins

Calicheamicins (CLMs) have strong lethality ability against Gram-positive and Gram-negative bacteria, and its antibacterial activities is 4000 times higher than Adriamycin. The anticancer spectrum of CLMs includes P388 leukemia (ID50 =5.0 μg/kg) and B16 melanoma (ID50 =1.25 μg/kg), which is higher than that of Doxorubicin by 4000 times. Since the toxicity of CLMs is too strong (ED50/LD50 < 10) and the scope of effective dose is too narrow, it is difficult to apply the CLMs alone in clinical practice. Therefore, the clinical application of CLMs is mainly used for immune-linked antibody drugs to directly target tumor cells. Since the development of monoclonal antibody technology, a variety of monoclonal antibody conjugated drugs have been made by carrying CLMs with monoclonal antibody as carrier, many of which have been used in clinic.

References

  1. Lee, M.D.; et al. Calicheamicins-discovery, structure, chemistry, and interaction with DNA. Accounts of Chemical Research, 1991, 24: 235-243.
  2. Damle, N.K.; et al. Antibody-targeted chemotherapy with immunoconjugates of calicheamicin. Current Opinion in Pharmacology, 2003, 3: 386–390.
* Only for research. Not suitable for any diagnostic or therapeutic use.

You May Also Be Interested In

From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.

Explore More ADC Products

Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.

ADC Cytotoxin

Powerful Targeted Cancer Solutions

ADC  Cytotoxin with Linker

Enhanced Stability And Efficacy

ADC Linker

Precise Conjugation For Success

Antibody-Drug  Conjugates (ADCs)

Maximized Therapeutic Performance

Auristatins

Next-Level Tubulin Inhibition

Calicheamicins

High-Impact DNA Targeting

Camptothecins

Advanced Topoisomerase Inhibition

Daunorubicins / Doxorubicins

Trusted Anthracycline Payloads

Duocarmycins

Potent DNA Alkylation Agents

Maytansinoids

Superior Microtubule Disruption

Pyrrolobenzodiazepines

Ultra-Potent DNA Crosslinkers

Traditional Cytotoxic Agents

Proven Chemotherapy Solutions

Cleavable Linker

Precise Intracellular Drug Release

Non-Cleavable Linker

Exceptional Long-Term Stability

Purity Guaranteed

≥95%
Purity Guaranteed

Countries/Regions Delivered

20+
Countries/Regions Delivered

Technical Support

24/7
Technical Support

Products In Stock

1,000+
Products In Stock

High-Quality Service

100%
High-Quality Service
Send Inquiry
Verification code
Inquiry Basket